Pharmacogenetics of anticancer monoclonal antibodies

Abstract

Pharmacogenetics is the study of therapeutic and adverse responses to drugs based on an individual’s genetic background. Monoclonal antibodies (mAbs) are a rapidly evolving field in cancer therapy, however a number of newly developed and highly effective mAbs (e.g., anti-CTLA-4 and anti-PD-1) possess pharmacogenomic profiles that remain largely undefined. Since the first chemotherapeutic mAb Rituximab was approved in 1997 by the US Food and Drug Administration for cancer treatment, a broad number of other mAbs have been successfully developed and implemented into oncological practice. Nowadays, mAbs are considered as one of the most promising new approaches for cancer treatment. The efficacy of mAb treatment can however be significantly affected by genetic background, where genes responsible for antibody presentation and metabolism, for example, can seriously affect patient outcome. This review will focus on current anticancer mAb treatments, patient genetics that shape their efficacy, and the molecular pathways that bridge the two.

Keywords

Pharmacogenetics / pharmacogenomics / immune-checkpoint proteins / monoclonal antibodies / cancer immunotherapy / personalized medicine

References

[1] Scott AM,Wolchok JD.Monoclonal antibodies in cancer therapy..Cancer Immun2012;12:14 PMCID:PMC3380347

[2] Coulson A,Gossell-Williams M.Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations..West Indian Med J2014;63:650-4 PMCID:PMC4663950

[3] Sgro C.Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review..Toxicology1995;105:23-9

[4] Cho A,Kulkarni AB.Generation of transgenic mice..Curr Protoc Cell Biol2009; PMCID:PMC3119260

[5] Hammers CM.Antibody phage display: technique and applications..J Invest Dermatol2014;134:1-5 PMCID:PMC3951127

[6] Kurosawa K,Ohta K.Chimeric antibodies..Methods Mol Biol2014;1060:139-48

[7] Liu JK.The history of monoclonal antibody development - progress, remaining challenges and future innovations..Ann Med Surg (Lond)2014;3:113-6 PMCID:PMC4284445

[8] Scheen AJ.International classification of various types of monoclonal antibodies..Rev Med Liege2009;64:244-7

[9] Goldenberg DM.Radiolabelled monoclonal antibodies in the treatment of metastatic cancer..Curr Oncol2007;14:39-42 PMCID:PMC1891189

[10] Baldo BA.Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses..Oncoimmunology2013;2:e26333 PMCID:PMC3827071

[11] Sallman DA,Ali S,Barnes JA.Rituximab hypersensitivity reactions (HSR): predictors of recurrent and severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease..J Clin Oncol2012;30:

[12] Weiss RB.Hypersensitivity reactions from antineoplastic agents..Cancer Metastasis Rev1987;6:413-32

[13] Nitta E,Sato T,Takeuchi K.A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study..Ann Oncol2007;18:364-9

[14] Le Guenno G,Charra L.Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura..Intern Med J2011;41:202-5

[15] Isabwe GAC,de Las Vecillas Sanchez L,Marquis K.Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes..J Allergy Clin Immunol2018;142:159-70.e2

[16] International HapMap CThe international HapMap project..Nature2003;426:789-96

[17] Lee NH.Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents..Anticancer Agents Med Chem2010;10:583-92 PMCID:PMC3770187

[18] Yan L.Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development..Biotechniques2005;39:565-8

[19] Ingelman-Sundberg M.Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy..Philos Trans R Soc Lond B Biol Sci2005;360:1563-70 PMCID:PMC1569528

[20] Yong WP,Ratain MJ.The role of pharmacogenetics in cancer therapeutics..Br J Clin Pharmacol2006;62:35-46 PMCID:PMC1885075

[21] Ryman JT.Pharmacokinetics of Monoclonal Antibodies..CPT Pharmacometrics Syst Pharmacol2017;6:576-88 PMCID:PMC5613179

[22] Dirks NL.Population pharmacokinetics of therapeutic monoclonal antibodies..Clin Pharmacokinet2010;49:633-59

[23] Qiu WQ,Brownstein BH,Ravetch JV.Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination..Science1990;248:732-5

[24] Ober RJ,Ghetie V.Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies..Int Immunol2001;13:1551-9

[25] Tabrizi MA,Roskos LK.Elimination mechanisms of therapeutic monoclonal antibodies..Drug Discov Today2006;11:81-8

[26] Inoue K.Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy..Drug Metab Pharmacokinet2014;29:12-9

[27] Yang F,Kemp CJ.Doxorubicin, DNA torsion, and chromatin dynamics..Biochim Biophys Acta2014;1845:84-9 PMCID:PMC3927826

[28] Korth-Bradley JM,Hanna RK,Lebsack ME.The pharmacokinetics of etanercept in healthy volunteers..Ann Pharmacother2000;34:161-4

[29] Baxter LT,Mackensen DG.Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice..Cancer Res1994;54:1517-28

[30] Keizer RJ,Schellens JH.Clinical pharmacokinetics of therapeutic monoclonal antibodies..Clin Pharmacokinet2010;49:493-507

[31] Fellner C.Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use..P T2012;37:503-30 PMCID:PMC3462607

[32] Berdeja J,Zonder J,Kaufman JL.Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study..Clin Lymphoma Myeloma Leuk2016;16:129-38

[33] Waldmann TA.Metabolism of immunoglobulins..Prog Allergy1969;13:1-110

[34] Kamath AV.Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies..Drug Discov Today Technol2016;21-22:75-83

[35] Gessner JE,Tamm A.The IgG Fc receptor family..Ann Hematol1998;76:231-48

[36] Musolino A,Bortesi B,Capelletti M.Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer..J Clin Oncol2008;26:1789-96

[37] Trotta AM,Romano C,Nappi A.Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy..Cancer Immunol Res2016;4:366-74

[38] Zhang W,Li J,Zhou DB.Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma..Chin Med J (Engl)2010;123:198-202

[39] Sachs UJ,Braeunlich CG,Bein G.A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter..Immunology2006;119:83-9 PMCID:PMC1782336

[40] Billiet T,Cleynen I,Ferrante M.A genetic variation in the neonatal Fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease..Am J Gastroenterol2016;111:1438-45

[41] Passot C,Renault S,Arnoult C.Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies..MAbs2013;5:614-9 PMCID:PMC3906315

[42] Wells A.EGF receptor..Int J Biochem Cell Biol1999;31:637-43

[43] Tran B,Tie J,Jiang ZQ.Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer..Cancer2011;117:4623-32 PMCID:PMC4257471

[44] Pietrantonio F,Coinu A,Borgonovo K.Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis..Eur J Cancer2015;51:587-94

[45] Wan PT,Roe SM,Niculescu-Duvaz D.Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF..Cell2004;116:855-67

[46] Xu JM,Wang YL,Liu T.PIK3CA mutations contribute to acquired cetuximab resistance in patients with metastatic colorectal cancer..Clin Cancer Res2017;23:4602-16 PMCID:PMC5559326

[47] Therkildsen C,Henrichsen-Schnack T,Nilbert M.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis..Acta Oncol2014;53:852-64

[48] Song DD,Li JH,Ma Y.Single nucleotide polymorphisms rs701848 and rs2735343 in PTEN increases cancer risks in an Asian population..Oncotarget2017;8:96290-300 PMCID:PMC5707100

[49] Holmes K,Thomas AM.Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition..Cell Signal2007;19:2003-12

[50] Sever R.Signal transduction in cancer..Cold Spring Harb Perspect Med2015;5:a006098 PMCID:PMC4382731

[51] Kieran MW,Cho YJ.The VEGF pathway in cancer and disease: responses, resistance, and the path forward..Cold Spring Harb Perspect Med2012;2:a006593 PMCID:PMC3543071

[52] Meadows KL.Anti-VEGF therapies in the clinic..Cold Spring Harb Perspect Med2012;2:a006577 PMCID:PMC3475399

[53] Schneider BP,Radovich M,Badve S.Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100..J Clin Oncol2008;26:4672-8 PMCID:PMC2653128

[54] Bocci G.Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle..Pharmacogenomics2011;12:1077-80

[55] Cao C,Fang JJ,Lv D.Polymorphism of vascular endothelial growth factor -2578C/A with cancer risk: evidence from 11263 subjects..Med Oncol2011;28:1169-75

[56] Wang K,Zhu ZM,Xin L.Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals..Cytokine2011;56:167-73

[57] Adjei AA.Blocking oncogenic Ras signaling for cancer therapy..J Natl Cancer Inst2001;93:1062-74

[58] Fiala O,Mohelnikova-Duchonova B,Matejka VM.G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab..Tumour Biol2016;37:6823-30

[59] Nakayama I,Matsushima T,Ogura M.Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients..BMC Cancer2017;17:38 PMCID:PMC5223326

[60] Renaud S,Falcoz PE,Romain B.Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations..Eur J Cardiothorac Surg2017;51:255-62

[61] Guerrero S,Farre L,Capella G.K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression..Cancer Res2000;60:6750-6

[62] Wang Y,Vanderlaan M.Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro..Angiogenesis2004;7:335-45

[63] Lamy A,Le Pessot F,Di Fiore F.Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls..Mod Pathol2011;24:1090-100

[64] Seidel JA,Kabashima K.Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations..Front Oncol2018;8:86 PMCID:PMC5883082

[65] Chambers CA,Egen JG.CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy..Annu Rev Immunol2001;19:565-94

[66] Buchbinder EI.CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition..Am J Clin Oncol2016;39:98-106 PMCID:PMC4892769

[67] Nomizo T,Tsuji T,Yasuda Y.Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients..Sci Rep2017;7:45124 PMCID:PMC5362817

[68] Tan D,Yi QH.Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer..Cancer Biomark2018;21:287-97

[69] Lee SY,Choi JE,Hong MJ.Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer..Gene2017;599:28-35

[70] Yeo MK,Seong IO,Kim JM.Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma..Hum Pathol2017;68:103-11

[71] Wang W,Mao Y,Sun J.A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma..Hum Genet2013;132:641-8

[72] Lee SY,Choi JE,Hong MJ.PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy..Sci Rep2016;6:25952 PMCID:PMC4867646

[73] Breunis WB,Chen R,Rosenberg SA.Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade..J Immunother2008;31:586-90 PMCID:PMC3276400

[74] Queirolo P,Laurent S,Piccioli P.Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study..Cancer Invest2013;31:336-45

[75] Queirolo P,Morabito A,Piccioli P.Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: an italian melanoma intergroup study..Front Immunol2017;8:386 PMCID:PMC5388686

[76] Palacios R,Elorza J.Genomic regulation of CTLA4 and multiple sclerosis..J Neuroimmunol2008;203:108-15

[77] Queirolo P,Morabito A,Carosio R.CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab..Eur J Cancer2018;97:59-61

[78] Kamps R,Bosch BJ,Xanthoulea S.Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification..Int J Mol Sci2017;18:E308 PMCID:PMC5343844

[79] Rizvi NA,Snyder A,Makarov V.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154